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Purpose: This multicenter, retrospective study evaluated treatment and clinical outcomes of 
patients with early stage breast cancer who received adjuvant high-dose rate (HDR) electronic 
brachytherapy (EBT) treatment post-lumpectomy using the Axxent® EBT system. Dosimetric 
data from the EBT treatment plans were compared with those based on iridium-192 HDR 
brachytherapy.
Material and methods: Medical records of 63 patients with early stage breast cancer (Tis, T1a, 
T1b, T1c, and T2) who were treated post-lumpectomy with EBT alone or in combination with 
external beam radiation therapy were reviewed. The prescribed EBT dose was 34 Gy (10 
fractions over 5 days, 3.4 Gy each) to 1 cm from the balloon surface. Dosimetry data from 
12 patients were compared with these of treatment plans using an iridium-192 source prepared 
for the same 12 patients.
Results: The majority of patients (90.5%) were older than 50 years and had one or more risk 
factors for breast cancer (80.6%). Tumor sizes were 0.1 cm to 3.5 cm (mean 1.3 cm). Median 
follow-up was 7 months (1 to 18 months) post-EBT. Balloon applicators were implanted 0 to 
85 days (mean 13.4 days) post-lumpectomy/re-excision. The most common adverse events 
were erythema, rash dermatitis, and pain or breast tenderness. No recurrences were reported. 
Dosimetric analyses demonstrated comparable target coverage, increased high-dose regions, 
and a significantly reduced dose to the ipsilateral breast and lungs as well as the heart with EBT 
as compared with the iridium-192 treatment plans.
Conclusion: This retrospective, multicenter study showed that postsurgical adjuvant radiation 
therapy for early stage breast cancer can be administered using the EBT system with similar 
toxicity outcomes to those reported with iridium-192 brachytherapy. EBT offers a convenient, 
portable, nonisotope alternative to HDR brachytherapy using iridium-192.
Keywords: electronic brachytherapy, breast cancer, radiation therapy
Introduction
An estimated 192,370 new cases of invasive and 54,000 noninvasive breast cancer 
were diagnosed in women in the United States in 2009.1 Breast-conserving surgery 
(BCS) followed by radiation therapy is a standard treatment option for early stage 
breast cancer.2 However, some patients elect to undergo mastectomy due to the length 
of radiation treatment after BCS, which can be 6 to 7 weeks of daily treatments. This 
time commitment can represent insurmountable logistical difficulties with regard to 
work or family responsibilities, leaving the patient to choose a more time-efficient, but 
debilitating, surgical outcome.3–5 Accelerated partial breast irradiation (APBI) offers 
patients a substantially reduced treatment time by directing radiation to the portion 
of the breast tissue most likely to experience recurrence, the tissue surrounding the OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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tumor cavity. APBI may reduce exposure to radiation of 
  nontarget tissue such as the heart and lungs when compared 
with whole breast irradiation6–8 and has demonstrated equiva-
lent control rates to whole breast irradiation following BCS 
in several studies.9–12
The majority of APBI techniques utilize an iridium-
192 source with an average energy of 383 kV . This form of 
radiation requires a high-dose-rate (HDR) afterloader unit 
and a shielded room, which is a financial burden to smaller 
institutions or clinics and can present scheduling challenges 
at higher volume centers. Electronic brachytherapy (EBT) 
utilizes a 50 kV X-ray source that does not require a well-
shielded radiation vault or an HDR afterloader unit, and 
the device can be easily moved from one procedure room 
to the next once regulatory requirements are met, allowing 
flexibility in scheduling patients. EBT also does not require 
the storage and handling of isotopes.13 Consequently, EBT 
may allow additional treatment centers to provide APBI to 
patients, increasing patients’ access to APBI and overall 
treatment choices.
The Axxent® EBT system (Xoft, Inc., Sunnyvale, CA) has 
been utilized for APBI in the United States since 2007. The 
X-ray source is inserted through a balloon applicator, which 
is implanted post-BCS into the tumor cavity. A controller 
powers the source and allows dose sculpting by moving the 
source through a range of dwell positions with dwell times 
chosen to achieve the prescription dose to the target tissue. In 
the initial, prospective, multicenter study of EBT in women 
with Stage 1–2 breast cancer, a prescription dose of 34 Gy 
was successfully delivered in 10 fractions over 5 days using 
this EBT system in 42 of 44 patients treated.7 A reduced dose 
(33.96 and 30.60 Gy) was delivered in the other two patients. 
To better understand how HDR EBT is utilized outside 
the context of a study protocol, a retrospective multicenter 
study was designed to collect data on treatment delivery and 
clinical outcomes in patients who received adjuvant radiation 
therapy with the EBT system for early stage breast cancer 
following BCS.
Materials and methods
eligibility
The medical records of 63 patients with early stage breast 
cancer who were treated post-lumpectomy using the EBT sys-
tem between April 2007 and November 2009 were reviewed. 
Records of patients treated with EBT alone or in combination 
with external beam radiation therapy (EBRT) were included. 
Records of patients previously or currently enrolled in 
other prospectively enrolling EBT studies were excluded. 
An Institutional Review Board for each participating 
center approved the protocol prior to commencing data 
  collection. The data were collected on case report forms and 
confidentiality was maintained at all times.
Data collection
Data on patient demographics and tumor characteristics, 
treatment, and follow-up were collected. For study sites 
willing to participate in a dosimetric comparison substudy, 
the EBT treatment plans from this retrospective study were 
compared to treatment plans created for the same patients for 
use with an iridium-192 source. An independent dosimetrist 
completed this subanalysis. The primary objective of this 
retrospective chart review is to report a real-world experience 
on the treatment and acute outcomes of patients treated with 
EBT, and provide a comparative dosimetric analysis of EBT 
with HDR therapy using iridium-192.
Definitions
Adverse events were recorded. Tumors were graded 
based on the American Joint Committee on Cancer 
(AJCC) classification where Tis = carcinoma in situ, 
T1a = tumor .0.1 cm but #0.5 cm in its greatest 
dimension, T1b = tumor .0.5 cm but #1 cm in its great-
est dimension, T1c = tumor .1 cm but #2 cm in its 
greatest dimension, T2 = tumor .2 cm but #5 cm in its 
greatest dimension, and Tmic = microinvasion = 0.1 cm in 
its greatest dimension. The histopathologic grades were based 
on G1 = well differentiated, G2 = moderately differentiated, 
G3 = poorly differentiated, G4 = undifferentiated, Gx = grade 
cannot be assessed, and NA = grade not available.
Materials
The EBT system (Axxent®, Xoft, Inc., Sunnyvale, CA) 
consists of the X-ray source, the balloon applicator, and the 
controller. The X-ray source comprises an X-ray tube in a 
multilumen catheter that allows cooling fluid to circulate over 
the tube. A sterile, disposable, single-use balloon applicator 
functions as a guide for the X-ray source. The EBT   controller 
provides power to the X-ray source and allows the X-ray 
source to be linearly translated within the applicator. The 
translation, or pullback movement, of the X-ray source within 
the applicator is designed to provide a conformal dose to the 
1-cm prescription point.
Treatment planning
The prescription dose and brachytherapy treatment plans were 
prepared individually for each patient based on   computed OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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tomography (CT) scans. BrachyVision™   treatment planning 
software (Varian Medical Systems, Palo Alto, CA) or Plato 
treatment planning software (Nucletron, Columbia, MD) were 
used at all centers. The measurement of the radiation dose 
(dosimetry) was based on Gy, which is the unit of absorbed 
radiation SI. Delivered dose was computed using TG-43 
parameters specific to this source.14 A balloon applicator was 
implanted following BCS and remained in place for the 5-day 
  treatment period.
Dosimetry
A retrospective analysis was conducted with the three-dimen-
sional CT image data from 12 patients using the BrachyVision 
treatment planning system to compare the dosimetry of the 
EBT source with that of an iridium-192 source (GammaMed-
Plus; Varian Medical Systems). The actual EBT treatment 
plans with the dwell times and positions used to treat each 
patient were included in the subanalysis. CT scans of the 
treated breast from the 12 patients were   digitally contoured 
to identify the balloon applicator, the clinical target volume 
(CTV), ipsilateral breast tissue, heart, lungs, skin, and ribs. A 
planning target volume (PTV) was obtained from each CTV 
from the surface of the CTV out to 1 cm from the balloon into 
the surrounding tissue. A comparison set of plans was created 
by replacing the EBT source with an iridium-192 source. 
The dwell times for the iridium-192 plans were optimized 
to deliver 34 Gy in 10 fractions to at least 95% of the PTV 
(D95), while minimizing the maximal dose to the PTV. 
Dose-volume histograms (DVH) for both source types were 
used for the dose comparison. The DVHs of each contoured 
structure on both plans were compared using the percent of 
the PTV receiving 90%, 100%, 150%, 200%, and 300% of 
the prescribed dose (V90, V100, V150, V200, and V300, 
respectively). Similarly, comparisons were made for each plan 
type for the percent of the ipsilateral breast volume receiving 
50% of the prescribed dose (Breast V50), the percent of the 
lung volume receiving 30% of the prescribed dose (Lung 
V30), and the percent of the heart volume receiving 5% of 
the prescribed dose (Heart V5). The maximum calculated 
doses to the skin and rib were compared. Lastly, the percent 
of the heart volume receiving more than 18 Gy for EBT and 
20 Gy for iridium-192 were compared.
statistics
Data were entered into an Access database (Microsoft, 
Redmond, WA) via paper case report forms. Analyses of the 
data were performed using SAS statistical analysis software 
(version 9.1.3; SAS Institute, Cary, NC). The n (number 
of observations) and proportion was reported for both the 
treatment success and acute outcome endpoints. For sum-
mary statistics of continuous variables, the n, mean, standard 
deviation, and range were presented. Variables that reflect 
categories of information were described using proportions 
and frequencies.
Results
Records at 13 clinical sites from 63 patients with Stage 1–2 
breast cancer were reviewed (Table 1). Nearly all were aged 
50 years and over (90.5%) and had one or more risk factors 
for breast cancer (80.6%), including family history of breast 
or other cancers, history of breast lesions,   post-menopausal, 
age at menarche, parity status, weight, and age. Tumor sizes 
ranged from 0.1 cm to 3.5 cm with a mean of 1.3 cm ± 0.8 cm. 
All patients had undergone BCS. Fifteen patients at seven 
study sites had re-excision due to positive margins (Table 1), 
Table 1 Patient characteristics
N (%)
number of patients 63 (100%)
Age range 
30–39 1 (1.6%)
40–49 5 (7.9%)
50–59 7 (11.1%)
60–69 30 (47.6%)
70–79 10 (15.9%)
80–89 9 (14.3%)
90–99 1 (1.6%)
AJCC classification
Tis 16 (25.4%)
Tla 9 (14.3%)
Tlb 8 (12.7%)
Tlc 19 (30.2%)
T2 7 (11.1%)
not documented 4 (6.3%)
Histopathologic grade
g1 23 (36.5%)
g2 18 (28.6%)
g3 15 (23.8%)
gx 2 (3.2%)
not documented 5 (7.9%)
Tumor size (cm)
Mean ± sD 1.3 ± 0.8
Median  1.2
range 0.1–3.5
Re-excision due to positive margins
Yes 15 (22.2%)
no 48 (77.8%)
Abbreviations: AJcc, American Joint committee on cancer; Tis, carcinoma in situ; 
T1a, tumor .0.1 cm but #0.5 cm in greatest dimension; T1b, tumor .0.5 cm but 
#1 cm in greatest dimension; T1c, tumor .1 cm but #2 cm in greatest dimension; 
T2, tumor .2 cm but #5 cm in greatest dimension; Tmic, micro-invasion = 0.1 
cm in greatest dimension; g1, well differentiated; g2, moderately differentiated;   
g3, poorly differentiated; g4, undifferentiated; gx, grade cannot be assessed.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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and two patients had positive margins at the time of treatment 
(Table 2). The median follow-up was 7 months, (range 
1 month to 18 months) after the last EBT treatment.
Balloon applicators were implanted a mean of 13.4 days 
(range 0 to 85 days) after the lumpectomy or last re-excision. 
Balloon sizes and their corresponding fill volumes are listed 
in Table 2. In one patient, an inflated balloon did not conform 
adequately to the tumor cavity; however, a second attempt at 
implantation was successful in this patient. In another patient, 
the balloon deflated a few hours after the implantation and 
was subsequently replaced. The applicator was returned to the 
device manufacturer, and it was determined that the deflation 
was caused by exposure of the applicator to a sharp object 
at the time of insertion.
The prescribed dose of radiation was 34 Gy at a depth 
of 1 cm from the balloon surface, which was to be delivered 
twice daily in 10 fractions of 3.4 Gy each. This prescription 
was delivered in 62 of 63 patients. For one patient, the CT 
scan showed that the balloon applicator was directly adjacent 
to the rib causing the rib to be within the PTV . Due to this 
proximity to the rib, the physician determined that a boost 
treatment followed by EBRT was the optimal course of 
treatment. The prescribed dose was 7.5 Gy, 2.5 Gy for three 
fractions, and EBRT was subsequently administered at 45 Gy 
in 25 fractions. The patient would have undergone 33 EBRT 
treatments without prior boost treatments.
Adverse events were recorded and if they were rated, the 
ratings were reported based on the Common Terminology 
Criteria for adverse events version 3 (CTCv3). Thirty-
five out of 63 patients experienced adverse events. The 
adverse events recorded during the treatments included one 
  occurrence for each of the following: grade 1 rash, grade 1 
nausea, grade 1 fatigue, and grade 1 rash dermatitis related 
to radiation. There was one occurrence of grade 2 rash 
dermatitis related to radiation. The most common adverse 
events reported during the follow-up period were erythema, 
rash dermatitis associated with radiation, and pain or breast 
tenderness. Twenty-six of the adverse events in 16 patients 
were not graded in   severity. All adverse events are listed in 
Table 3. One occurrence of a grade 4 rash dermatitis associ-
ated with chemoradiation was reported as a radiation recall 
  reaction in a patient for whom doxorubicin hydrochloride 
and cyclophosphamide administration commenced 10 days 
after the final fraction. The rash was almost fully healed 
18 days later, which was 28 days after the final fraction. The 
6-month visit showed hypopigmentation and the last visit at 
10-month follow-up showed erythema that was treated with 
hydrocortisone cream. One occurrence of a grade 3 moist 
desquamation occurred in one patient and had improved to 
erythema grade 1 at 4 months after the final fraction. No 
other severe reactions were reported as related to treatment. 
One patient died from Stage 4 pancreatic cancer 294 days 
after their last EBT treatment.
The occurrence of a seroma was reported in five patients 
(7.9%). Out of the five patients, two seromas required drain-
age and the other three were observed. Four patients (6.3%) 
experienced infections and were treated with oral antibiotics. 
One patient was thought to have an infection and underwent 
debridement of tissue. Upon examination of the debrided 
tissue, it was determined that this patient (1.6%) had fat 
necrosis and not an infection. No other cases of fat necrosis 
were reported.
Individual treatment plans were prepared for each patient 
prior to beginning EBT. For the dosimetric comparison sub-
study, separate treatment plans for an iridium-192 source were 
Balloon applicator sizes and fill volume
3–4 cm 4–5 cm1 5–6 cm Not 
Documented2
n 16 38 4 4
Saline volume (cc)
Mean ± sD 38.2 ± 5.5 51.3 ± 11.2 91.3 ± 33.3 51.7 ± 10.7
Median 36.5 50.0 100.0 50.6
Min 30.0 35.0 45.0 40.0
Max 45.0 95.0 120.0 65.5
Notes: 1One patient in the 4–5-cm group did not have saline volume documented; 
2Four patients had saline volume documented without a balloon applicator size.
Abbreviations: sD, standard deviation; min, minimum; max, maximum.
Table 2 Treatment summary
Time (days) from lumpectomy or re-excision to applicator 
placement 
Mean ± sD 13.4 ± 14.1
Median 9.0
range 0–85
Time (days) from applicator placement to first fraction
Mean ± sD 3.8 ± 1.7
Median 4.0
range 0–7
Balloon surface to skin distance (mm)
Mean ± sD 14.2 ± 6.6
Median 11.8
range 7.0–36.0
Margin pathology status
negative 61 (96.8%)
Positive 2 (3.2%)
Balloon applicator size
3–4 cm 16 (25.4%)
4–5 cm 39 (61.9%)
5–6 cm 4 (6.3%)
not Documented 4 (6.3%)OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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prepared based on the EBT treatment plans from 12 patient 
records in this study, with identical PTVs (mean and SD 
104.9 ± 9.6 mL, range 86.0–123.0 mL). The prescribed 
doses were identical (34 Gy) except for the one patient only 
treated for three fractions (2.5 Gy per fraction, 7.5 Gy total) 
as described above. The active treatment lengths for EBT vs 
iridium-192 were identical for 10 of the 12 patients, ranging 
from 2.5 cm to 4.5 cm, with two cases requiring an additional 
dwell point for iridium-192 to achieve optimal PTV dose 
  coverage. The DVH metrics for PTV and organ dose coverage 
for the two sets of treatment plans are compared in Table 4. 
The percent of the PTV receiving 100% of the prescribed 
dose (V100) was not statistically different between the two 
treatment modalities. The V150, V200, and V300 were sig-
nificantly higher (P , 0.05) for EBT than iridium-192. The 
V90 was lower for EBT than iridium-192. The maximum 
calculated dose to the skin and rib were not significantly dif-
ferent between the two sources. The Breast V50, Lung V30, 
and Heart V5 were significantly lower with EBT as compared 
with iridium-192. Of the 12 patients with reviewed dosimetry, 
no patient received more than 12 Gy (total dose) to any part 
of the heart with EBT, while one patient would have received 
as much as 21.0 Gy to the heart with an iridium-192 plan 
with 1% of the volume of the left ventricle receiving at least 
20.3 Gy. The patient with fat necrosis had a V150 of 44.6 mL 
and a V200 of 19.5 mL.
Discussion
This retrospective, multicenter study represents an analysis 
of acute toxicity in patients treated with EBT as postsurgical 
adjuvant therapy for early stage breast cancer and provides a 
comparative dosimetric analysis of the EBT treatment plans 
with those based on an iridium-192 HDR source in a subgroup 
of patients. The study population of this retrospective study 
included a broader range of patients and greater variation in 
the treatment regimens than would be seen in a prospective 
study, which would specify patient selection criteria and a 
treatment protocol. A previous study of this EBT system 
treated 44 patients with tumor sizes up to 2.8 cm,7 whereas 
this study enrolled patients with slightly larger tumor sizes of 
up to 3.5 cm and included two patients with positive margins 
at the time of treatment. The prescribed dose of radiation, 
34 Gy to a depth of 1 cm beyond the balloon   surface, was 
delivered in 62 of 63 patients. As part of a clinical study 
program in which 176 patients have been treated with EBT,7,15 
this study demonstrates that APBI can be delivered utilizing 
a technology that provides benefits to the patients and the 
healthcare providers. The EBT technology can be stored with-
out shielding, and treatment can be conducted in a standard 
patient room with minimal shielding. This provides a benefit 
to patients, who have greater accessibility to   radiation treat-
ment and may be more compliant with completing adjuvant 
radiation treatment. Patient scheduling may be facilitated 
Table 3 Number (%) of adverse events that were possibly, probably, or definitely related to treatment during treatment or follow-up 
for all 63 patients
Adverse event N (%) of 
adverse events
CTC grade1 (n) Not 
graded (n)
1 2 3 4
erythema 14 (22.2%) 7 1 0 0 6
rash dermatitis associated with radiation2 10 (15.9%) 4 4 0 1 2
Pain/breast tenderness 10 (15.9%) 6 1 0 0 3
rash/dry desquamation 5 (7.9%) 2 0 0 0 3
hypopigmentation 5 (7.9%) 5 0 0 0 0
hyperpigmentation 5 (7.9%) 2 0 0 0 3
seroma 5 (7.9%) 1 1 0 0 3
infection 4 (6.3%) 0 2 0 0 2
Moist desquamation3 3 (4.8%) 0 2 1 0 0
Pruritis 2 (3.2%) 1 0 0 0 1
Fatigue 2 (3.2%) 1 0 0 0 1
Ulceration of treated breast 2 (3.2%) 0 2 0 0 0
skin sensitivity 1 (1.6%) 0 0 0 0 1
Fat necrosis 1 (1.6%) 0 0 0 0 1
Telangiectasia 1 (1.6%) 0 1 0 0 0
Fibrosis 1 (1.6%) 1 0 0 0 0
induration 1 (1.6%) 1 0 0 0 0
Notes: 1common Terminology criteria (cTc) version 3 grade provided if reported; 2One event reported as a grade 4 radiation recall was resolved 2.5 months after 
radiation treatment; 3One event reported as a grade 3 moist desquamation was resolved 4 months after radiation treatment.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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since the device can be easily moved from one procedure 
room to the next.
Treatment was well tolerated and the adverse events 
recorded in this study are generally within the range of grade 
and frequency reported in other EBT studies,7,15 as well as in 
studies of iridium-192 brachytherapy with a similar duration 
of follow-up.16 The infection rate was 6.3%, which is within 
the range of 2.9% to 11.4% previously reported with EBT7,15 
and within the range of 4% to 16% previously reported with 
iridium-based balloon brachytherapy (Ir-BT).16–20 Fat necrosis 
was reported in one patient at 406 days post treatment. 
Previous studies have shown a correlation between fat necro-
sis and dose hot spots with interstitial brachytherapy.21,22 
Wazer et al reported a mean V150 of 69 mL and V200 of 
22 mL in patients with fat necrosis.21 In this study, the mean 
V150 and V200 were 46 mL and 22 mL, respectively, for 
the dosimetric substudy population and 45 mL and 20 mL, 
respectively, for the patient with fat necrosis. Beitsch et al 
reported one-year follow-up data on 37 patients treated with 
EBT, none of whom had fat necrosis.15 Mehta et al reported 
two cases of fat necrosis in a study population of 44 patients 
with follow-up times of up to 18 months.7 The mean V150 
and V200 were 52 mL and 24 mL, respectively, for the study 
population. It remains to be seen whether additional reports 
of fat necrosis will occur as these patients reach 2 years of 
follow-up. In the future, it will be interesting to compare the 
rates of fat necrosis from these EBT studies with a currently 
enrolling study that has limited the V150 to 50 mL and the 
V200 to 10 mL for IrBT.23 Five-year follow-up data from 
the initial IrBT study showed fat necrosis in 4 of 43 (9.3%) 
patients at 11, 14, 42, and 63 months. Three-year follow-up 
data from an IrBT registry reported fat necrosis in 22 of 1,440 
(1.5%) patients.24
Skin toxicity of grade 4 occurred in one patient who had 
initiated treatment with chemotherapeutic agents, cyclophos-
phamide and doxorubicin hydrochloride, within 10 days of 
the completion of the final EBT fraction. The skin toxicity 
was almost fully healed at 18 days after the final fraction and 
resolved at 2.5 months following the final fraction. Previous 
studies have suggested that careful selection and timing of 
administration of chemotherapeutic agents must be considered 
for patients receiving radiation therapy. As with iridium-192 
APBI treatments, radiation recall may occur in patients who 
receive cytotoxic chemotherapeutic agents following APBI, 
particularly in the presence of thin skin bridges or other factors 
that could result in an increased dose to the skin.7,25 Appropriate 
patient selection and the timing of administration of cytotoxic 
chemotherapeutic agents in relation to the radiation therapy 
treatments, as with patients being treated with iridium-192, 
must be taken into account when treating patients with EBT.
EBT may also be used in combination with EBRT. In 
this study, one patient received EBT treatment as a boost 
dose (7.5 Gy) followed by EBRT (45 Gy), which provided 
an optimal treatment for this patient whose tumor cavity was 
adjacent to a rib. The use of EBT for a boost dose decreased 
the required number of EBRT treatments for this patient 
from 33 to 25 fractions. EBT has been used as a boost dose 
and as sole radiation therapy intra-operatively with surgical 
staff remaining in the operating room during irradiation; 
one-year data from the single-center intraoperative radiation 
therapy (IORT) study demonstrated good cosmesis with no 
recurrences.26 A multicenter IORT study randomized patients 
to whole breast EBRT or intra-operative EBT as sole therapy 
or as a boost dose prior to EBRT and demonstrated good 
control rates at 4 years of followup.27
Comparative treatment plans based on an iridium-
192 source were prepared using data from the EBT treatment 
plans for 12 patients in this study. The required number of 
dwell positions varied between the two treatments in two 
Table  4  Dosimetry  comparison:  outcomes  with  electronic 
brachytherapy (eBT) and iridium-192
Mean ± SD Iridium-192 
(n = 12)
EBT 
(n = 12)
P-value 
–
Mean PTV dose in gy 22.3 ± 14.4 27.7 ±16.6 –
  range 11.9–45.4 13.1–51.4 –
V90 in mL 96.4 ± 3.3 93.7 ± 4.7 P , 0.05
  range 90.0–99.8 84.9–98.7 –
V100 in mL 87.2 ± 6.1 87.2 ± 6.0 ns
  range 78.8–94.9 78.3–94.5 –
V150 in mL 30.0 ± 6.1 46.3 ± 6.3 P , 0.05
  range 20.3–38.1 37.0–56.8 –
V200 in mL 6.5 ± 3.2 22.3 ± 5.1 P , 0.05
  range 0–11.2 14.5–30.3 –
V300 in mL 0 3.8 ± 2.4 P , 0.05
  range 0 0–7.8 –
Maximum skin  
dose in gy
33.3 ± 7.9 33.7 ± 10.5 ns
  range 20.0–47.0 16.0–48.0 –
Maximum rib dose  
in gy
26.9 ± 17.8 29.7 ± 27.3 ns
  range 4.0–59.0 1.0–83.0 –
ipsilateral breast  
V50 in mL
217.0 ± 48.7 141.8 ± 44.0 P , 0.05
  range 147.0–299.0 96.0–225.0 –
ipsilateral lung  
V30 in mL
23.3 ± 30.6 8.0 ± 12.9 P , 0.05
  range 0–90.5 0–36.0 –
heart V5 in mL 41.5 ± 29.6 13.1 ± 20.9 P , 0.05
  range 1.0–82.1 0–57.3 –
Abbreviations: PTV, planning target volume; sD, standard deviation.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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of 12 cases due to the different inherent dose distributions 
  produced by each source, and this variation was not considered 
to be clinically relevant. As the plans were designed specifi-
cally to deliver a desired dose to the PTV , no difference in 
V100 would be expected; however,   differences were noted 
with other variables that are consistent with other compari-
sons of these two types of brachytherapy.6,8,13 Hot spots within 
the PTV were more common with EBT as shown by the V150, 
V200, and V300 values. However, doses to normal tissue in 
the ipsilateral breast, lung, and heart were significantly less 
with EBT as compared to iridium-192. Skin doses in the sub-
analysis were not significantly different when comparing the 
EBT group to the Iridium group. With an 11.8 mm median 
skin bridge margin (for all 63 patients), which is beyond 
the normalized PTV prescription point of 1 cm, significant 
  differences would not be expected. The results of this dosim-
etric comparison are similar to those reported in an IrBT study 
with a dosimetric substudy comparing the actual IrBT data 
with EBT treatment plans created for the same patients.6 The 
similarities in outcomes provide confirmation of the value 
of generating hypothetical treatment plans from data used to 
create actual treatment plans. The clinical relevance of the 
differences in dosimetry between an electronic source and 
an iridium source remain to be seen; however, the potential 
for   clinical relevance may provide an additional factor to 
consider in the decision about the methodology of radiation 
therapy for each patient.
The dose to the heart is of concern as a correlation has 
been shown in the literature between diminished myocardial 
perfusion over 6 to 24 months and the percent of the left 
ventricle (LV) that receives a threshold dose over 25 Gy with 
standard 2 Gy per day EBRT.28 Marks et al reported that at 
6 and 12 months postradiation, patients with ,1% of the LV 
receiving this threshold dose had a 4% and 12% incidence 
of perfusion defect.28 For patients with 1% to 5% of the LV 
above the threshold dose, the defect rate at 6 and 12 months 
was 22% and 27%, respectively. The threshold dose will be 
different for hypo-fractionated APBI where the equivalent 
LV dose threshold for an iridium-192 5-day APBI schedule 
is 20.3 Gy.29 Using the same method as Garza et al,29 and 
assuming a relative biological effectiveness value of 1.2 for 
50 kV X-rays, the LV threshold dose for APBI with EBT is 
18.7 Gy. For EBT, no patient was at risk for cardiac perfu-
sion effects; by contrast, one of 12 patients with iridium-192 
would have been borderline at-risk with 1% of the LV over 
the equivalent 20.3 Gy threshold. Determining a specific risk 
for a 1% volume of LV radiation out of the 1% to 5% volume 
cohort is not possible. As succinctly noted by Mille, a clinical 
treatment methodology which minimizes dose to any critical 
organ is desirable, particularly for the heart.8
Conclusion
This retrospective, multicenter study showed that postsurgical 
adjuvant radiation therapy for early stage breast cancer can 
be administered using the EBT system with similar toxicity 
outcomes to those reported with iridium-192 brachytherapy. 
Dosimetric analyses demonstrated comparable target cover-
age, increased high dose regions, and a significantly reduced 
dose to the ipsilateral breast and lungs as well as the heart 
with EBT as compared with the iridium-192 treatment plans. 
EBT offers a convenient, portable, nonisotope alternative to 
HDR brachytherapy using iridium-192.
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